MADISON, VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.
VistaGen, a biotechnology company based in South San Francisco, is one of the world's leading companies focused on using the power of stem cell technology to transform the ways drugs are discovered and tested. WARF is the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, one of the top-ranked public research universities in the U.S.
The licensed patents result from the research of stem cell pioneer James Thompson of the University of Wisconsin Stem Cell and Regenerative Medicine Center and director of regenerative biology at the new Morgridge Institute for Research. The license will accelerate VistaGen's commercial programs focused on providing customized, next-generation, stem cell-based predictive toxicology and drug discovery screening assays to increase preclinical research and development (R&D) productivity for the pharmaceutical industry.
"This agreement with WARF is another critical step in our strategy to become a 'one-stop-shop' for the world's premier stem cell differentiation systems," says Ralph Snodgrass, VistaGen's CEO. "It enhances our fundamental expertise for capturing the value of human embryonic stem cell biology for predictive toxicology, drug discovery screening and drug development. When combined with our strong stem cell-based intellectual property estate, the key terms of the new license provide a strong foundation to support our commercial programs focused on high-end R&D services, strategic discovery collaborations and enabling licenses."
"We are very pleased to have signed a licensing agreement with VistaGen," says Andy DeTienne, WARF's licensing manager for stem cell technologies. "VistaGen's approach to the commercialization of hum
|Contact: Janet L. Kelly|
University of Wisconsin-Madison